Among HER2-positive breast cancers, patients with level of HER2 higher than 2200 amol/μg were considered as superexpressors and had significant higher DFS and OS than non superexpressors when they were treated with anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.